NCT03178188 is a Phase 2, PHASE3 clinical trial of Pulsed-dye Laser in Lupus Erythematosus, Discoid, sponsored by Chulalongkorn University.

Who is sponsoring NCT03178188?

NCT03178188 is sponsored by Chulalongkorn University.

What drugs are being tested in NCT03178188?

Interventions in NCT03178188: Pulsed-dye Laser, Sham.

What condition does NCT03178188 study?

NCT03178188 studies Lupus Erythematosus, Discoid.

Is NCT03178188 still recruiting?

NCT03178188 is currently status unknown. Last updated 6 June 2017.

Last reviewed 2017-06-06 · How we verify

NCT03178188

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy of 595 nm Pulsed-dye Laser in Treatment of Discoid Lupus Erythematosus

Status unknown Phase 2, PHASE3 Last updated 6 June 2017

What this trial tests

Phase 2, PHASE3 trial testing Pulsed-dye Laser in Lupus Erythematosus, Discoid in 24 participants. Status unknown.

Timeline

15 December 2016

Primary endpoint
14 December 2017

14 December 2017

Quick facts

Lead sponsor	Chulalongkorn University
Phase	Phase 2, PHASE3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	24
Start date	15 December 2016
Primary completion	14 December 2017
Estimated completion	14 December 2017
Sites	1 location across Thailand

Drugs / interventions tested

Pulsed-dye Laser
Sham

Conditions studied

Lupus Erythematosus, Discoid — all drugs for Lupus Erythematosus, Discoid →

Sponsor

Chulalongkorn University

Who can join

18 and older, any sex, with Lupus Erythematosus, Discoid. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

forty DLE lesions from patients will be recruited in the study. The lesions on one side of the body were block-randomized into the treatment group and the other side served as a control. The patients can continue their systemic treatments and the PDL is designed to be used as an adjunctive treatment. Treatments with the PDL will be delivered in the treatment group every 4 weeks for 4 consecutive months while the lesions in the control group received a sham. The patients will be evaluated at baseline (week 0), week 4, 8, 12, and at follow-up period of 4, 12 weeks after the final treatment (week 16, 24). Erythema index (EI), Texture index (TI) will be obtained and digital photographs will be taken and modified Cutaneous Lupus Erythematosus Disease Area and Severity Index (mCLASI) will be assessed in every visit. The digital photographs will later be evaluated by 3-blinded dermatologists. Moreover, side effects and patients' satisfaction score will also be recorded.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Lupus Erythematosus, Discoid

Currently open trials in the same condition.

NCT04857034 — A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Active Discoid and/or Subacute Cutaneous · Phase 2 · active not recruiting

Other Chulalongkorn University trials

Trials by the same sponsor.

NCT07458659 — Clinical Study of BCMA-Targeted CAR T-Cell Injection in the Treatment of Patients With Relapsed/Refractory Multiple Myel · EARLY_PHASE1 · not yet recruiting
NCT07346118 — Fluid Balance Guided by Modified Venous Excess Ultrasonography Versus Standard Care in Patients With Acute Kidney Injury · NA · not yet recruiting
NCT07388862 — Comparison of Treatment Outcome of Pulpotomy With Versus Without Dental Operating Microscope in Carious Mature Permanent · EARLY_PHASE1 · not yet recruiting
NCT07373977 — Comparison of Postoperative Pain After Pulpotomy Performed With Versus Without Dental Operating Microscope in Carious Ma · EARLY_PHASE1 · not yet recruiting
NCT07078929 — Clinical Trial of CMD63 Chimeric Antigen Receptor T-cell (CAR T-cell) in Children With Acute Lymphoblastic Leukemia (ALL · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03178188 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chulalongkorn University
Last refreshed: 6 June 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03178188.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing